Abstract 7P
Background
RNA modifications play an important role in gene expression and cellular functions. Regulatory genes for RNA modifications, such as methyltransferase 1, tRNA methylguanosine (METTL1) and adenosine deaminase RNA specific B1 (ADAR2), have been correlated with cancer progression due to their effects on mRNA and tRNA editing.
Methods
In this study, the association between polymorphisms in 25 RNA modification regulatory genes and the prognosis of 744 non-small cell lung cancer (NSCLC) patients was evaluated. Among the 21 single nucleotide polymorphisms (SNPs) studied, three were significantly associated with the overall survival (OS) of patients.
Results
The SNP rs10877013T>C in METTL1 gene was significantly associated with better OS (under a dominant model, adjusted hazard ratio [aHR] = 0.67, 95% confidence interval [CI] = 0.48-0.93, P = 0.02). METTL1 rs10877013 is located in intronic region, so rs703842G>A located in METTL13′untranslated region (3′UTR) with a strong LD (D′ = 1.0 and r2 ≥ 0.9) was found. The SNPs rs3788152A>C and rs414743G>A in the ADAR2 gene were associated with significantly worse OS (under a dominant model, aHR = 1.46, 95% CI = 1.05-2.03, P = 0.03; under a codominant model, aHR = 1.40, 95% CI = 1.02-1.93, P = 0.04, respectively). A dual luciferase assay showed a significantly higher promoter activity of METTL1 with the rs703842 A allele than with the G allele in H1299 (P = 6.5×10-6) and H1703 lung cancer cells (P = 0.03). Knockdown of METTL1 with specific siRNA induced cell apoptosis and decreased cell proliferation, invasion, and migration in lung cancer cells.
Conclusions
In conclusion, the investigation reveals that genetic variations METTL1 rs10877013T>C, ADAR2 rs3788152A>C, and ADAR2 rs414743G>A polymorphisms within RNA modification regulatory genes are associated with survival outcomes of NSCLC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1792P - Molecular characterization from IMfirst: Atezolizumab plus chemotherapy in extensive-stage small cell lung cancer (ES-SCLC) in Spain
Presenter: Manuel Cobo Dols
Session: Poster session 07
1793P - Treatment and outcomes of limited disease small cell lung cancer (LD-SCLC) in the Canadian small cell lung cancer database (CASCADE)
Presenter: Sara Moore
Session: Poster session 07
1794P - Deciphering ERBB2-driven mechanisms that regulate tumor immune evasion and metastasis in SCLC
Presenter: Lydia Meder
Session: Poster session 07
1795P - Consolidation serplulimab following concurrent hypofractionated chemoradiotherapy for limited-stage SCLC: Preliminary analysis of phase II ASTRUM-LC01 study
Presenter: Yuqi Wu
Session: Poster session 07
1796P - Smoking-related genomic mutation patterns in patients with small cell lung cancer treated in ASTRUM-005 study
Presenter: Ying Cheng
Session: Poster session 07
1798P - Relapsed and refractory systemic therapy real-world outcomes in the Canadian small cell lung cancer database (CASCADE)
Presenter: Sara Moore
Session: Poster session 07
1799P - Efficacy and safety of integrating consolidative thoracic radiotherapy with immunochemotherapy in ES-SCLC: A real-world retrospective analysis
Presenter: Qi Zhang
Session: Poster session 07
1800P - Breaking chemo-immunotherapy resistance in SCLC-patient derived tumor with novel DDRi combinations
Presenter: Carminia Della Corte
Session: Poster session 07
1801P - Expression analysis of Fuc-GM1 ganglioside in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) with BMS-986012, nivolumab, and carboplatin-etoposide
Presenter: Kenneth O'Byrne
Session: Poster session 07